Bromfenac
Antiinflammatory Agents, Non-Steroids
Sold as Yellox · PROLENSA · BROMSITE 0.075%
- Drug class
- Antiinflammatory Agents, Non-Steroids
- Availability
- Prescription only
- Routes
- Ophthalmic
- Markets covered
- 4
- Products on record
- 10
- FDA reports (12 mo)
- 117
Overview
Plain-language summary, compiled from the cited regulatory records
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) [1]. It is classified as an anti-inflammatory agent [1].
Bromfenac is approved for treating postoperative inflammation and reducing ocular pain in patients who have undergone cataract surgery [1]. It is available under various brand names, including BROMSITE [1].
In the past 12 months, there have been 117 adverse event reports associated with bromfenac [2]. The most frequently reported issues include product use problems, eye pain, product dose omission, product packaging quantity issues, and hallucinations [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 4 | August 1, 2025 |
| US United States | FDA | 2 | January 8, 2026 |
| EU European Union | EMA | 1 | April 8, 2026 |
| GB United Kingdom | MHRA | 3 | February 27, 2026 |
CACanada· Health Canada
4 products
Uses
AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 3 WARNINGS AND PRECAUTIONS .................................................................................
4 ADVERSE REACTIONS ................................................................................................... 6 DRUG INTERACTIONS ...................................................................................................
8 DOSAGE AND ADMINISTRATION ............................................................................... 8 OVERDOSAGE ..................................................................................................................
9 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 10 STORAGE AND STABILITY ......................................................................................... 11 SPECIAL HANDLING INSTRUCTIONS .......................................................................
USUnited States· FDA
2 products
Uses
09% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction (1) .
How to take
EUEuropean Union· EMA
1 product
Uses
Yellox is indicated in adults for the treatment of postoperative ocular inflammation following cataract extraction .
How to take
GBUnited Kingdom· MHRA
3 products
3 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [4].
Drug interactions
Known interactions involving Bromfenac. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 267. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 02439123 · revised August 1, 2025
- [2]FDA DailyMed · 08a0591e-6cb3-30… · revised October 26, 2023 [PDF]
- [3]European Medicines Agency · EMEA/H/C/001198 · revised April 8, 2026
- [4]MHRA (UK) · PLPI163781374 · revised January 30, 2026
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.